IMMUNOREX® HOPE OF AFRICA !

Gratuit
Recevez toutes nos informations et actualités par Email.

Entrez votre adresse email:

New Research: On 8 and 9 June the city of Chicago (Illinois/USA) will host the International Conference of Retroviruses and Novel drugs against HIV/AIDS. This conference will explore advances in research of new drugs in the fight against HIV. Also for understanding the fundamental mechanisms of retroviruses.

On this occasion a Gabonese researcher Professor Donatien Mavoungou (Biochemist) was invited as a speaker for his work on the IMMUNOREX® called molecule. Particularly with regard to the restoration and strengthening the immune system while blocking the replication of the HIV virus.

This molecular complex using DHEA (dehydroepiandrosterone), which is an androgen which has been used successfully in particular a vaccine against influenza.  The IMMUNOREX® treatment has been tested on more than 2,000 HIV-positive patients over a period of 8 years, as well as other infectious diseases such as malaria, as well as cardiovascular disease. It was proposed to WHO in the context of the epidemic Ebola in Guinea.

After having successfully completed its Phase III, it was shown properties on opportunistic diseases main consequences of causes of death by HIV. A clinical study is soon to start in Ivory Coast as part of the resistance to antiretrovirals or Immunorex could intervene successfully in this context that requires the patient to have to change not without problems treatment.

The treatment may be administered orally (tablet or caplets) or by injection.

The subject of the conference Prof Mavoungou will explain all the interest to be used as a booster Immunorex® in the therapeutic vaccine candidate program TAT OYI developed by French firm Biosantech. This association aimed to optimize the effectiveness of anti-HIV therapeutic vaccine using the next Tat protein.

Biosantech the French company will soon publish the results of its Phase IIa clinical trial in Marseille on 48 volunteer patients. If this candidate therapeutic vaccine will be the first successful vaccine therapy in the world for the treatment of patients infected with HIV.

Based on the results obtained by Immunorex®, Prof Mavoungou what was offered on the occasion of the Chicago conference meetings with various pharmaceutical companies North American industry.

We will follow with great interest the development of the project or the contribution of Africa will be déterminente in the treatment of the HIV epidemic.

Helene Mastone

sources : Institute IIDSRSI / Health News / Global Science

  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »